Nanogen officials last week pinned the future of their company on the success of a new sales organization, royalties from a company it acquired late last year, and a broadening line of products for the clinical diagnostics market.

“We are a very different company than we used to be,” Robert Saltmarsh, the company’s chief financial officer, told BioArray News last week.

The San Diego-based company reported a 51-percent slide in revenues and an 89-percent increase in net losses for the fourth quarter of 2004.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.